शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

BSEKerala Ayurveda Ltd· Pharmaceuticals & BiotechnologyLowNeutral
Announced Tue, 15 Jul, 2025 · 14:56 IST

Kerala Ayurveda Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2025 ,inter alia, to consider and approve the unaudited quarterly results ....

Revenue declinedProfit growth above 25%EBITDA margin compressionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.5%Reaction day
₹586.55
prior close
₹580.00
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.2%-1.7% vs market
Pharmaceuticals peers, median of 149sector+0.5%-1.0% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
+1.2
15m
+1.2
30m
+0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.5+1.2-1.7+0.5-1.0
Next day
-0.3+1.7-2.0+0.8-1.1
2d
-0.3+2.0-2.3+1.2-1.5
3d
+1.1+1.4-0.3+0.8+0.3
4d
-0.2+1.3-1.5+0.3-0.6
5d
-0.8+1.2-2.1-0.1-0.7
1w
-7.8+0.7-8.5+0.1-7.9
15d
-14.2-2.7-11.4-3.3-10.9
1m
-12.2-3.4-8.8-4.2-8.0
2m
-16.3-1.3-15.0-3.1-13.2
3m
-27.5-3.7-23.9-6.3-21.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kerala Ayurveda Ltd has informed the BSE that its Board of Directors will meet on Friday, 18th July 2025 to consider and approve the unaudited financial statements (both standalone and consolidated) for the quarter ended 30th June 2025 (Q1 FY26). This is a routine regulatory filing under SEBI's Listing Obligations and Disclosure Requirements. The trading window for dealing in the company's shares has been closed from 1st July 2025 for designated persons and will reopen 48 hours after the results are announced. No financial figures or business details are disclosed in this filing — only the meeting schedule and procedural compliance.

Likely market impact

No immediate impact on shareholders as this is just a calendar announcement. Investors should watch for the actual Q1 results on 18th July 2025, which will reveal revenue, profit, and margin trends for the quarter and likely drive the next stock price move.

By the numbersConsolidated · Q1 FY26 vs Q1 FY25
Q1 FY26Q1 FY25Change
Revenue₹28.61 Cr₹28.64 Cr−0.1%
Operating profit−₹6.66 Cr−₹0.01 Crloss widened
Profit after tax₹2.03 Cr₹0.46 Cr+340.9%
EBITDA margin-14.6%2.8%−17.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.